Mankyu Park
Director/Miembro de la Junta en Coagulant Therapeutics, Inc. .
Cargos activos de Mankyu Park
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
Coagulant Therapeutics, Inc.
 Coagulant Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Coagulant Therapeutics, Inc. is a privately held company that focuses on designing, developing, and commercializing therapeutics for the coagulation cascade and its adjacencies. Coagulant Therapeutics is based in Berkeley, CA. The company's lead product candidate, CT-001, is a next-generation Factor VIIa designed for enhanced efficacy and safety in the setting of acute bleeding. The company is also developing additional therapeutics targeted to APC for the treatment of acute bleeding and other coagulation cascade-related diseases. The company was founded in 2019 by Terry Hermiston, who has been the CEO since then. | Director/Miembro de la Junta | - | - |
Historial de carrera de Mankyu Park
Antiguos cargos conocidos de Mankyu Park.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| DTCP Management GmbH | Corporate Officer/Principal | - | - |
Formación de Mankyu Park.
| Goizueta Business School-Emory | Undergraduate Degree |
Estadísticas
Internacional
| Estados Unidos | 3 |
| Corea del Sur | 2 |
Operativa
| Director/Board Member | 1 |
| Corporate Officer/Principal | 1 |
| Undergraduate Degree | 1 |
Sectorial
| Health Technology | 2 |
| Finance | 2 |
| Consumer Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas privadas | 2 |
|---|---|
Coagulant Therapeutics, Inc.
Coagulant Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Coagulant Therapeutics, Inc. is a privately held company that focuses on designing, developing, and commercializing therapeutics for the coagulation cascade and its adjacencies. Coagulant Therapeutics is based in Berkeley, CA. The company's lead product candidate, CT-001, is a next-generation Factor VIIa designed for enhanced efficacy and safety in the setting of acute bleeding. The company is also developing additional therapeutics targeted to APC for the treatment of acute bleeding and other coagulation cascade-related diseases. The company was founded in 2019 by Terry Hermiston, who has been the CEO since then. | Health Technology |
| DTCP Management GmbH | Finance |
- Bolsa de valores
- Insiders
- Mankyu Park
- Experiencia
